Abstract
This manuscript describes the discovery and characterization of inhibitors of the lipid phosphatase SHIP2, an important target for the treatment of Type 2 diabetes, using the Automated Ligand Identification System. ALIS is an affinity selection-mass spectrometry platform for label-free, high throughput screening of mixture-based combinatorial libraries. We detail the mass-encoded synthesis of a library that yielded NGD-61338, a pyrazole-based SHIP2 inhibitor. Quantitative ALIS affinity measurements and inhibition of SHIP2 enzymatic activity indicate that this compound has micromolar binding affinity and inhibitory activity for this target. This inhibitor, which does not contain a phosphatase “warhead,” binds the active site of SHIP2 as determined by ALIS-based competition experiments with the enzymes natural substrate, phosphatidylinositol 3,4,5-triphosphate (PIP3). Structure-activity relationships for NGD-61338 and two other ligand classes discovered by ALIS screening were explored using a combination of combinatorial library synthesis and ALIS-enabled affinity ranking in compound mixtures.
Keywords: Affinity selection, mass spectrometry, high throughput screening, label-free, SHIP2, ALIS
Combinatorial Chemistry & High Throughput Screening
Title: Inhibitors of the Lipid Phosphatase SHIP2 Discovered by High Throughput Affinity Selection-Mass Spectrometry Screening of Combinatorial Libraries
Volume: 12 Issue: 8
Author(s): D. Allen Annis, Cliff C. Cheng, Cheng-Chi Chuang, John D. McCarter, Huw M. Nash, Naim Nazef, Todd Rowe, Robert J.M. Kurzeja and Gerald W. Shipps Jr.
Affiliation:
Keywords: Affinity selection, mass spectrometry, high throughput screening, label-free, SHIP2, ALIS
Abstract: This manuscript describes the discovery and characterization of inhibitors of the lipid phosphatase SHIP2, an important target for the treatment of Type 2 diabetes, using the Automated Ligand Identification System. ALIS is an affinity selection-mass spectrometry platform for label-free, high throughput screening of mixture-based combinatorial libraries. We detail the mass-encoded synthesis of a library that yielded NGD-61338, a pyrazole-based SHIP2 inhibitor. Quantitative ALIS affinity measurements and inhibition of SHIP2 enzymatic activity indicate that this compound has micromolar binding affinity and inhibitory activity for this target. This inhibitor, which does not contain a phosphatase “warhead,” binds the active site of SHIP2 as determined by ALIS-based competition experiments with the enzymes natural substrate, phosphatidylinositol 3,4,5-triphosphate (PIP3). Structure-activity relationships for NGD-61338 and two other ligand classes discovered by ALIS screening were explored using a combination of combinatorial library synthesis and ALIS-enabled affinity ranking in compound mixtures.
Export Options
About this article
Cite this article as:
Annis Allen D., Cheng C. Cliff, Chuang Cheng-Chi, McCarter D. John, Nash M. Huw, Nazef Naim, Rowe Todd, Kurzeja J.M. Robert and Shipps Jr. W. Gerald, Inhibitors of the Lipid Phosphatase SHIP2 Discovered by High Throughput Affinity Selection-Mass Spectrometry Screening of Combinatorial Libraries, Combinatorial Chemistry & High Throughput Screening 2009; 12 (8) . https://dx.doi.org/10.2174/138620709789104870
DOI https://dx.doi.org/10.2174/138620709789104870 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design Chronotherapeutic Drug Delivery Systems - An Approach to Circadian Rhythms Diseases
Current Drug Delivery Pain Perception and Management: Where do We Stand?
Current Molecular Pharmacology Immune Endocrinological Evaluation in Patients with Severe Vascular Acquired Brain Injuries: Therapeutical Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets Isolation and Structural Characterization of a Peptide from the Venom of Scorpion with Toxicity Towards Invertebrates and Vertebrates
Protein & Peptide Letters Editorial (Hot Topic: PI3K/AKT and mTOR/p70S6K1 Signaling Pathways in Human Cancer)
Current Cancer Drug Targets Role of Signaling Pathways in Mesenchymal Stem Cell Differentiation
Current Stem Cell Research & Therapy ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Current Medicinal Chemistry Current Concepts and Controversies in the Use of Antenatal Corticosteroid Therapy for Prevention of Neonatal Morbidities
Current Women`s Health Reviews Identification of Novel Key Targets and Candidate Drugs in Oral Squamous Cell Carcinoma
Current Bioinformatics Evolution of Mannose 6-Phosphate Receptors (MPR300 and 46): Lysosomal Enzyme Sorting Proteins
Current Protein & Peptide Science Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Hypertension in Older Patients
Current Hypertension Reviews Phase IV Studies: Some Insights, Clarifications, and Issues
Current Clinical Pharmacology Identification of a Novel Inhibitor of the NF-κB Pathway
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Current Pharmaceutical Design Objectively Assessed Physical Activity and Sedentary Behaviour During Pregnancy in Portuguese Women: Differences Between Trimesters and Weekdays and Weekends
Current Women`s Health Reviews The Relationship between Diet and Frailty in Aging
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroprotective Effects of Lithium - Pointing out Protein Phosphatases as Drug Targets?
Current Medicinal Chemistry - Central Nervous System Agents